Novanta 3Q 2026: Revenue $305.01M, EPS $0.05 — 10-Q Summary

Novanta reported 3Q 2026 revenue of $305.01M, up 23.1% YoY, but net income fell 81.1% to $2.02M due to higher costs. Automation segment revenue rose 16%, while Medical Solutions grew 30.3%, including $32.9M from Riverpoint Medical acquisition. Gross margins varied across segments.

Original reporting
Published Nov 9, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novanta 3Q 2026: Revenue $305.01M, EPS $0.05 — 10-Q Summary — source image
Decision brief

The 30-second read

$NOVTBearishMed
01

Why it matters

The earnings miss may trigger short‑term sell pressure, but the revenue beat and acquisition synergies could be viewed positively over a longer horizon.

02

Market read

Primary earnings disclosure for a small‑cap medical‑technology firm; fresh numbers may move the stock in after‑hours trading.

03

What to watch

Restructuring charges are expected to taper off by 1Q 2027, which may improve margins in future quarters.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Novanta Inc. filed its Q3 2026 Form 10‑Q, reporting revenue growth driven by the recent Riverpoint Medical acquisition and higher segment demand.

Company-level read

Ticker impact

$NOVTBearishHigh confidence
Context

Q3 2026 revenue rose 23.1% YoY to $305.01M, but diluted EPS fell to $0.05, an 83.3% decline from the prior quarter.

Expected impact

likely downside pressure as the market prices in the sharp EPS decline and higher acquisition-related costs.

Evidence & confidence

Revenue beat is offset by a steep earnings drop and higher SG&A, R&D, and amortization charges, which typically weigh on the stock.

Market effects

Medical solutions segment shows strong growth from the Riverpoint Medical acquisition, potentially benefiting peers in minimally invasive surgical consumables.

No immediate regional impact beyond the company's operating markets.

Limited to investors tracking small-cap medical device and automation technology stocks.

Counterpoint

Despite the EPS miss, the 23% revenue growth and successful integration of Riverpoint could support a longer‑term upside if costs normalize.

Key entities

  • Novanta Inc.

    US‑listed medical device and automation technology company (ticker NOVT).

  • Riverpoint Medical

    Acquired minimally invasive surgical consumables business contributing $32.9M of Q3 revenue.

Related articles

$NOVTHighAI 8/10

Why is Novanta stock tumbling today?

Novanta (NOVT) shares fell 14.7% after Q3 2026 earnings call, with GAAP operating margin dropping to 4.6% from 11.5% YoY. Adjusted EPS guidance for Q4 was reduced to $0.91–$0.96, below consensus of $1.02. Insider selling and macroeconomic concerns added to the decline, with shares hitting an intraday low of $120.24.

$NOVTMedAI 8/10

Novanta earnings beat by $0.11, revenue topped estimates

Novanta (NOVT) reported Q3 EPS of $1.05, beating estimates by $0.11, with revenue at $305M, surpassing expectations of $262.82M. The company provided Q4 and FY 2026 guidance, with EPS and revenue estimates generally in line with or slightly below consensus. NOVT's stock is down 12.72% over the last 3 months but up 40.37% year-over-year.

$NOVTHigh

Novanta: Q3 Earnings Snapshot

Novanta Inc. (NOVT) reported Q3 net income of $2M, or 5 cents per share, with adjusted earnings of $1.05 per share. Revenue was $305M. For Q4, it forecasts earnings of 91-96 cents per share and revenue of $306M-$312M. Full-year earnings are expected to be $3.66-$3.71 per share, with revenue of $1.14B.

$NOVTHigh

Novanta Announces Financial Results

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial Results for the Third Quarter 2026 • Third Quarter 2026 GAAP Revenue increased 23% to $305 million • Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted EBITDA increased 38% to $80 million